Glioblastoma is an aggressive brain tumor that affects an estimated 12,000 people per year, with poor overall prognosis and long-term survival rates. Northwestern Medicine scientists are at the forefront of leading-edge investigations to discover the roots of glioblastoma’s origins, and to pinpoint innovative new treatments to attack this deadly disease.
Measuring epigenetic signatures in blood plasma could help classify brain tumors, according to a study published in Nature Medicine.
The elevated expression of a gene called LY6K was correlated with increased cancer cell growth and resistance to radiation therapy in glioblastoma, according to a recent Northwestern Medicine study.
A previously unknown migration of glioblastoma may explain why current treatments stall out over time, according to a new study.
A new lipid nanoparticle drug helped make tumor cells more vulnerable to therapy, significantly prolonging survival in models of glioblastoma.
A recent Northwestern Medicine study found that patients with glioblastoma responded better or worse to immunotherapy depending on the presence of certain mutations in their tumors.
A Northwestern Medicine study has demonstrated the role of dopamine in the progression of glioblastoma and suggests that targeting the neurotransmitter may slow cancer growth.
Northwestern Medicine scientists have identified a gene, called isocitrate dehydrogenase 3-alpha, that promotes tumors in grade IV glioblastoma, according to a study published in Science Advances.